Analysis of antidepressants presented on the pharmaceutical market of the Kyrgyz Republic

Mental disorders make up a significant part of the overall global burden of disease, with depression and anxiety among the top ten main causes leading to disability between the ages of 10 and 49. Due to the fact that antidepressants are mainly used in the pharmacotherapy of depression and anxiety disorders, the purpose of our research was to segment the pharmaceutical market of antidepressants in the Kyrgyz Republic. The database of the State Register of Medicines of the Department of Medicines and Medical Devices of the Ministry of Health of the Kyrgyz Republic, registered and approved for medical use in the Kyrgyz Republic, was used for the analysis. The methods of content analysis, observation, comparison, grouping, and ranking were used. Currently, 24 drugs from the group of antidepressants are officially approved for medical use in the Kyrgyz Republic. The maximum number of deliveries to the country in monetary terms was carried out in 2021, amounting to 42 210 339 soms or 496,523 USA dollars. The sales leaders from the antidepressant group are the drugs amitriptylline, paroxetine (rexetin®) and escitalopram (sevpram®). The study identified problems with the physical availability of antidepressants in the country